Jupiter Neurosciences logo

Jupiter NeurosciencesJUNS

NASDAQ

Pharmaceuticals

$3.09+0.00%

No cached AI snapshot yet for JUNS.

Be the first to run a multi-agent analysis on this ticker.

Key Stats

$16.88MMarket cap
$3.3352-week high
$0.3152-week low
120,530Avg volume (30d)

5 employees36.28M shares outstandinglisted 2024-12-03

Next earnings ~May 5, 2026

About Jupiter Neurosciences

Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

Latest News

Showing market-wide stock news

Related Stocksin Pharmaceuticals

Ready to see the live AI view on JUNS?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing JUNS side-by-side with live signals.

Jupiter Neurosciences (JUNS) Hold? Multi-Agent AI Analysis